COMPANY

TRIANA Biomedicines, Inc.

HQ: Lexington, MA source · trianabio.com ↗

Also known as Trianabio · 1 source

Keywords: oncology cancer small molecule lung non-small cell carcinoma ALK-positive NSCLC ALK-Positive Lung Cancer ALK-positive Non-small Cell Lung Cancer TRI-611

Location: Lexington, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $120.06M (Form D filed Dec 4, 2025). SEC Form D 0001815337-25-000003 (Dec 4, 2025)
Evidence (1 event)
- Dec 4, 2025 · SEC Form D 0001815337-25-000003
  Name of Issuer: Triana Biomedicines, Inc.; CIK: 1815337; Address: Lexington, MA; Submission type: D; Filing date: 2025-12-04; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120061960; Total Amount Sold: 120061960; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Mar 11, 2026 Trial start 1: A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC source ↗

Upcoming milestones

May 31, 2029 (ESTIMATED) · 1 · A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC · NCT07491497

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07491497	A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC	1	Recruiting	Mar 11, 2026	May 31, 2029 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗